BRPI0716107A2 - mÉtodos para preparar cÉlulas de langerhans ou cÉlulas dendrÍticas e para diferenciar monàcitos, modelo de cÉlulas, monàcitos cd14+ congelados, uso de pelo menos um modelo de cÉlula e/ou de pelo menos um modelo de tecido, e, mÉtodos para produzir um modelo de tecido, e uma pele reconstruÍda ou uma mucosa reconstruÍda - Google Patents

mÉtodos para preparar cÉlulas de langerhans ou cÉlulas dendrÍticas e para diferenciar monàcitos, modelo de cÉlulas, monàcitos cd14+ congelados, uso de pelo menos um modelo de cÉlula e/ou de pelo menos um modelo de tecido, e, mÉtodos para produzir um modelo de tecido, e uma pele reconstruÍda ou uma mucosa reconstruÍda

Info

Publication number
BRPI0716107A2
BRPI0716107A2 BRPI0716107-7A2A BRPI0716107A BRPI0716107A2 BR PI0716107 A2 BRPI0716107 A2 BR PI0716107A2 BR PI0716107 A BRPI0716107 A BR PI0716107A BR PI0716107 A2 BRPI0716107 A2 BR PI0716107A2
Authority
BR
Brazil
Prior art keywords
model
methods
monocytes
reconstructed
tissue
Prior art date
Application number
BRPI0716107-7A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Nicolas Bechetoille
Valerie Andre
Isabelle Orly
Eric Perrier
Original Assignee
Basf Beauty Care Solutions F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Beauty Care Solutions F filed Critical Basf Beauty Care Solutions F
Publication of BRPI0716107A2 publication Critical patent/BRPI0716107A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C12N5/0698—Skin equivalents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/09—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
    • C12N2502/094—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells keratinocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/09—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
    • C12N2502/097—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells oral mucosa cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/24—Genital tract cells, non-germinal cells from gonads
    • C12N2502/243—Cells of the female genital tract, non-germinal ovarian cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cosmetics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI0716107-7A2A 2006-09-04 2007-09-03 mÉtodos para preparar cÉlulas de langerhans ou cÉlulas dendrÍticas e para diferenciar monàcitos, modelo de cÉlulas, monàcitos cd14+ congelados, uso de pelo menos um modelo de cÉlula e/ou de pelo menos um modelo de tecido, e, mÉtodos para produzir um modelo de tecido, e uma pele reconstruÍda ou uma mucosa reconstruÍda BRPI0716107A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0653567A FR2905380B1 (fr) 2006-09-04 2006-09-04 Procede de production de cellules de langerhans et/ou de cellules de dentritiques interstitielles/dermiques a partir de monocytes cd14+
PCT/EP2007/059165 WO2008028882A1 (en) 2006-09-04 2007-09-03 A method for producing langerhans cells and/or dermal/interstitial dentritic cells from cd14+ monocytes

Publications (1)

Publication Number Publication Date
BRPI0716107A2 true BRPI0716107A2 (pt) 2013-09-24

Family

ID=37781699

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0716107-7A2A BRPI0716107A2 (pt) 2006-09-04 2007-09-03 mÉtodos para preparar cÉlulas de langerhans ou cÉlulas dendrÍticas e para diferenciar monàcitos, modelo de cÉlulas, monàcitos cd14+ congelados, uso de pelo menos um modelo de cÉlula e/ou de pelo menos um modelo de tecido, e, mÉtodos para produzir um modelo de tecido, e uma pele reconstruÍda ou uma mucosa reconstruÍda

Country Status (7)

Country Link
EP (1) EP2064318A1 (cg-RX-API-DMAC7.html)
JP (1) JP2010502175A (cg-RX-API-DMAC7.html)
KR (1) KR20090049620A (cg-RX-API-DMAC7.html)
BR (1) BRPI0716107A2 (cg-RX-API-DMAC7.html)
CA (1) CA2662231A1 (cg-RX-API-DMAC7.html)
FR (1) FR2905380B1 (cg-RX-API-DMAC7.html)
WO (1) WO2008028882A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010225438A1 (en) * 2009-03-17 2011-10-13 The Heart Research Institute Ltd Method of cell differentiation and uses therefor in screening, diagnosis and therapy
GB201700138D0 (en) 2017-01-05 2017-02-22 Senzagen Ab Analytical methods and arrays for use in the same
US20220025337A1 (en) * 2018-11-30 2022-01-27 Shiseido Company, Ltd. Pigmentation skin model and method for producing same, and method for evaluating factor for treating or preventing pigmentation of skin
EP3991797A4 (en) * 2019-09-17 2023-06-14 Toppan Inc. CELL STRUCTURE AND METHODS OF PRODUCTION THEREOF
FR3132146B1 (fr) * 2022-01-27 2025-10-31 Genoskin Modèle humain ex vivo destiné à l’évaluation du potentiel vaccinal d’une composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2743817B1 (fr) * 1996-01-23 1998-03-13 Oreal Equivalent de peau comprenant des cellules de langerhans
US7566568B2 (en) * 2001-04-27 2009-07-28 Istituto Superiore Di Sanita Method for generating highly active human dendritic cells from peripheral blood mononuclear cells
FR2833271B1 (fr) * 2001-12-10 2004-09-17 Coletica Production de cellules dendritiques in vitro a partir de monocytes cd14+, pour notamment la realisation de modeles cellulaires et/ou tissulaires en suspension, en monocouches et tridimentionnels; utilisation de ces modeles
WO2005007839A1 (ja) * 2003-07-22 2005-01-27 Kirin Beer Kabushiki Kaisha ノッチリガンドDelta-1、GM-CSF、TGF-βを用いたヒト末梢血単核球であるCD14陽性細胞からのランゲルハンス細胞の調製方法

Also Published As

Publication number Publication date
EP2064318A1 (en) 2009-06-03
JP2010502175A (ja) 2010-01-28
CA2662231A1 (en) 2008-03-13
FR2905380A1 (fr) 2008-03-07
WO2008028882A1 (en) 2008-03-13
FR2905380B1 (fr) 2008-12-05
KR20090049620A (ko) 2009-05-18

Similar Documents

Publication Publication Date Title
IL294095B1 (en) Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
HUS1900038I1 (hu) Nátrium-glükóz kotranszporter-2 inhibitorai és alkalmazási eljárásaik
BR112012005710A2 (pt) método para produzir células megacariotícas maduras, método para produzir um produto de plaqueta, método para produzir um produto sanguíneo, população celular, composição celular congelada e kit
BRPI0819936A2 (pt) Preparação farmacêutica, método para produzir células dendríticas, células dendríticas, composição farmacêutica, e, uso de uma célula dendrítica ou uma preparação.
CY2018026I2 (el) Χρηση στρωματικων βλαστοκυτταρων λαμβανομενων απο λιπωδη ιστο στην θεραπεια συριγγιου
IL193702A (en) Pharmaceutical preparation containing human embryonic stem cells, methods of manufacture and use thereof
BRPI0812638A2 (pt) "método para diminuir a pressão em um indivíduo método para reduzir inflamação vascular em um indivíduo, composição farmacêutica para diminuira pressão sanguínea em um indivíduo e uso de uma composição"
BRPI0923589A2 (pt) uso de uma composição espumável essencialmente livre de ingredientes farmaceuticamente ativos para o tratamento da pele humana.
BRPI0906261A2 (pt) "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente"
BRPI0912292A2 (pt) composições e métodos para o uso de células no tratamento do tecido cardíaco.
BRPI0817290A2 (pt) Métodos, dispositivos, sistemas, conjuntos, e kits para retração de tecido dentro de uma cavidade oral
IL223376A0 (en) Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
WO2005113747A3 (de) Multizelluläre gewebe- und organkultursysteme
WO2008073635A3 (en) Automatable artificial immune system (ais)
WO2007108835A3 (en) Automatable artificial immune system (ais)
WO2007117765A3 (en) Ex vivo generated tissue system
WO2006114098A3 (en) Biocompatible material for surgical implants and cell guiding tissue culture surfaces
BRPI0718114A2 (pt) método para estimular a produção de fator de crescimento por células de sangue de cordão umbilical humano, método in vitro para expandir células de sangue de cordão umbilical humano, e, método para melhorar sobrevivência e crescimento de células de sangue de cordão umbilical humano transplantadas em um indivíduo
IL212580A0 (en) Cells modified to express lipid - linked oligosaccharide flippase activity, methods of producing the same and uses thereof
BR112012001344A2 (pt) derivados de 17hidróxi-17-pentafluoroetil-estra-4,9(10)-dieno-11-arila, método de produção destes e uso destes para o tratamento de doenças
BR112014002718A2 (pt) célula, população de célula, composição farmacêutica e kit para uso no tratamento de uma doença de degeneraçãoretinal
ATE519777T1 (de) Magnetosomen-genexpression in eukaryotischen zellen
BR112012022238A2 (pt) pele artificial
BRPI0915255A2 (pt) célula t assassina natural foxp3+; população de células; e método para produção e aumento do número de células t assassinas naturais foxp3+; método para administrar uma célula t assassinanatural ao fígado ou ao tecido da mucosa em um indivíduo, e para suprimir uma resposta imunológica em órgão de um indivíduo, e composição farmacêutica
BRPI0919489A2 (pt) composição, kit, métodos de tratamento de uma doença reumática, e de artrite reumatóide em um paciente, agente capaz de ativar células t reguladoras cd4+cd25+ e metotrexato, e, uso de um agente capaz de ativar células t reguladoras cd4+cd25+ e metotrexato

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.